BNTC — Benitec Biopharma Share News
0.000.00%
Last trade - 00:00- $301.79m
- $121.82m
Benitec Biopharma Inc reports results for the quarter ended September 30 - Earnings Summary
Benitec Biopharma Inc expected to post a loss of 55 cents a share - Earnings Preview
Brief: Benitec Biopharma files for mixed shelf of up to $125 mln
U.S. RESEARCH ROUNDUP- Cadence Design Systems, Equity Bancshares, S&P Global
Brief: Benitec Biopharma Inc Co Entered Into Sales Agreement With Leerink Partners Llc
Benitec Biopharma Inc expected to post a loss of 78 cents a share - Earnings Preview
Brief: Suvretta Capital Management Reports A Stake Of 19.99% In Benitec Biopharma
Brief: Benitec Biopharma Reports Positive Interim Clinical Trial Data For First OPMD Subject Treated With BB-301 In Phase 1b/2a Study
Brief: Benitec Biopharma Inc Files For Mixed Shelf Of Up To $125 Million
Brief: Benitec Biopharma Releases Q2 2024 Results And Provides Operational Update
Benitec Biopharma Inc reports results for the quarter ended in December - Earnings Summary
Benitec Biopharma Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Benitec Biopharma Announces First Subject Dosed In Phase 1B/2A Clinical Trial For Gene Therapy Candidate BB-301
Benitec Biopharma Inc expected to post a loss of $3.23 a share - Earnings Preview
Brief: Adage Capital Partners, L.P Reports 7.50% Passive Stake In Benitec Biopharma - SEC Filing
Brief: Citadel Advisors Reports 6.9% Passive Stake In Benitec Biopharma Inc. As Of Aug 11, 2023- SEC Filing
Brief: Benitec Biopharma Inc. Announces Pricing Of $30 Million Underwritten Public Offering
Brief: Benitec Biopharma Announces 1-For-17 Reverse Stock Split Effective July 26, 2023
Benitec Biopharma jumps as FDA clears muscle disorder drug study